Cluster of differentiation 44 (CD44) expression in breast carcinoma is associated with basal-like epithelial markers in tumor cells, advanced tumor stage, and metaplastic variants. Since CD44 is a recently identified marker, further research is necessary to understand its immunoexpression and its relationship with hormone receptor status and other prognostic factors that influence patient management and therapy. This evidence concerns the gene CD44 and neoplasm.